Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events
Clinical trial NCT07694414 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07694414
- Sponsor
- Inge Marie Svane
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-01
- Primary completion
- 2028-08-01
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.